Evidence map›Paper›PMID 40747461›Full record

ArticleBladder (San Francisco, Calif.)2025

Pentosan polysulfate alleviates interstitial cystitis/bladder pain syndrome by modulating bile acid metabolism and activating the TGR5 receptor through gut microbiota regulation.

Zhangrui Zhu, Yuexuan Zhu, Qi Sun, Jingwen Xue, Ming Xie, Yao Yu, Benlin Wang, Wentai Shangguan, Zhengyuan Feng, Peng Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bladder (San Francisco, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhangrui ZhuDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Yuexuan ZhuDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Qi SunDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Jingwen XueDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Ming XieDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Yao YuDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Benlin WangDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Wentai ShangguanDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Zhengyuan FengDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Peng WuDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The disrupted gut microbiome has been found to be implicated in the development of interstitial cystitis/bladder pain syndrome (IC/BPS). Pentosan polysulfate (PPS) is an oral medication used for treating IC/BPS, acting as both an anti-inflammatory agent and a bladder barrier protector. However, the precise mechanisms by which the PPS-mediated modulation of the gut microbiome alleviates IC/BPS are not fully understood. Objective: This study aimed to identify the key gut microbiota species and metabolites involved in PPS's protective effects against IC/BPS. Methods: We employed a multifaceted approach, including 16S rDNA gene sequencing, antibiotic treatment, and fecal microbiota transplantation, to validate the dependency of PPS's protective effects on the gut microbiome. Furthermore, we performed a comprehensive metabolomic profiling using non-targeted metabolomics and liquid chromatography-tandem mass spectrometry. Results: PPS significantly elevated the abundance of the xylan-degrading bacteria, Conclusion: PPS exerts its protective effects against IC/BPS by modulating the gut microbiome and its metabolites.

Indexed as

Bladder barrierCyclophosphamideGut microbiotaInterstitial cystitis/bladder pain syndromePentosan polysulfateUrsodeoxycholic acid

Identifiers

PMID40747461
PMCPMC12308114

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.